David L. Porter

4 ta ish

University of Pennsylvania

1. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

   Stephan A. Grupp, Michael Kalos, David M. Barrett +10

   MaqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.082765

2. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493

3. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

   Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17

   MaqolaOAOchiq kirish20232 iqtibos

   ABIABI:AkademIndex/2026.other.102947

4. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

   Melody Smith, Anqi Dai, Guido Ghilardi +46

   Maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.480531